Figure 3From: Dose-escalation of human anti-interferon-α receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label studyMedian fold change of type I IFN gene signature by visit for subjects with positive baseline gene signature. A. In Whole Blood in Single-Dose Groups; B. In Whole Blood in Multiple-Dose Groups; C. In Skin in Single-Dose Groups; D. In Skin in Multiple-Dose Groups. IFN, interferon.Back to article page